EirGenix Inc. (TPEX: 6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
82.70
-1.00 (-1.19%)
Sep 10, 2024, 1:30 PM CST
-11.36%
Market Cap 25.32B
Revenue (ttm) 1.13B
Net Income (ttm) -842.30M
Shares Out 306.21M
EPS (ttm) -2.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 321,390
Open 84.00
Previous Close 83.70
Day's Range 82.60 - 85.00
52-Week Range 72.20 - 111.00
Beta 0.62
Analysts n/a
Price Target n/a
Earnings Date Nov 11, 2024

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2023, EirGenix's revenue was 1.02 billion, a decrease of -30.95% compared to the previous year's 1.48 billion. Losses were -915.21 million, 692.1% more than in 2022.

Financial Statements

News

There is no news available yet.